Centessa Pharmaceuticals plc Annual Report - How They Did This Year

This guide helps you understand Centessa’s performance over the past year. Use this "cheat sheet" to decide if the company fits your investment goals.

1. What does this company do?

Centessa is a pharmaceutical company based in London with research teams in Boston. They use a "hub-and-spoke" model, managing several independent, specialized subsidiaries. This allows each program to act like a nimble startup while receiving support from the parent company.

They focus on areas with few treatment options, specifically sleep disorders and blood or immune system diseases. Because they do not sell products yet, their value depends entirely on the success of their clinical trials.

2. Financial performance

Centessa is currently in a "spending" phase, prioritizing research over profit. For the year ending December 31, 2025, the company reported a $185 million loss, mostly due to $140 million in research costs.

As of March 2026, they had 154.2 million shares outstanding. With $310 million in cash and investments, management expects to fund operations into the second half of 2027. They aim to use partnerships and stock sales to keep the company running while managing the number of shares outstanding.

3. Major wins and challenges

The biggest win is the March 2026 deal with Eli Lilly. Centessa licensed certain sleep disorder programs to Lilly for an immediate $100 million. They could earn over $500 million more in milestone payments, plus future royalties.

However, competition is fierce. Their lead drug, cleminorexton, must prove it is safer and more effective than existing treatments from companies like Takeda to justify its value.

4. Financial health and risks

Centessa is an "emerging growth company," meaning it requires significant cash and faces high regulatory hurdles.

• The "Burn" Reality: The company has lost over $750 million since it began. Costs will likely rise as they move into expensive, late-stage clinical trials.
• Debt Constraints: A $50 million loan from Oxford Finance comes with strict rules. If the company fails to maintain enough cash, the lender could demand immediate repayment or seize the company’s patents.
• Market Sensitivity: The company relies on the stock market to fund its work. A downturn in the biotech sector could force them to pause trials or accept financing that reduces your ownership stake.

5. What could go wrong?

Investing in Centessa is a high-stakes bet on their clinical trials.

• Trial Failure: If a lead drug like cleminorexton fails a major trial, the company’s value could drop significantly.
• Intellectual Property: Their business relies on patents. If these are challenged or fail to protect their drug formulas, competitors could copy their work.
• Global Instability: They rely on outside research organizations to run trials. Geopolitical conflicts can disrupt supply chains and delay patient recruitment, pushing back important data results.

6. Future outlook

Centessa is focused on hitting key clinical milestones. Their success depends on the Eli Lilly partnership, which provides both cash and expert validation. Watch for upcoming data from their sleep disorder trials. These results will determine if the company can move toward FDA approval and eventual commercial success.

Investor Tip: Before deciding, ask yourself if you are comfortable with the "all-or-nothing" nature of clinical-stage biotech. If you are looking for steady dividends or immediate profits, this may not be the right fit. If you are looking for long-term growth potential and believe in the science behind their sleep disorder programs, keep a close eye on their next round of clinical data.